Strategic report Corporate governance Financial statements Financial statements Company cash flow statement Notes to the Company financial statements For the year ended 31 December 2016 For the year ended 31 December 2016 2016 2015 44.
Adoption of new and revised standards $m $m The impact on the Company of new and revised standards is the same as for the Group.
Details are given in Note 1 to the consolidated Profit before tax 73 133 financial statements.
Adjustments for: Depreciation, amortisation and impairment of: Amortisation of intangible assets 3 1 45.
Significant accounting policies Gains losses on disposal of intangible assets 26 The separate financial statements of the Company are presented as required by the Companies Act 2006.
As permitted by that Act, the Cost of equity-settled employee share scheme 5 3 separate financial statements have been prepared in accordance with International Financial Reporting Standards adopted for use in the Finance income 15 4 European Union.
Interest and bank charges 53 33 The financial statements have been prepared on the historical cost basis.
The principal accounting policies adopted are the same as those Change in other current assets 1 set out in Note 2 to the consolidated financial statements with the addition of the policies noted below.
Change in other payables 2 1 Investments in subsidiaries are stated at cost less, where appropriate, provisions for impairment.
Change in inventory 4 Change in other receivables 1 1 Equity-settled employee share schemes are accounted for in accordance with IFRS 2 Share based payment, whereby current charge Change in amounts due from to subsidiaries 13 15 expenses relating to the subsidiaries employees are recharged to subsidiary companies.
Change in other current liabilities 3 5 Release of contingent Liability 4 46.
Intangible assets Non-cash dividend from subsidiaries 3 Product related Net cash from operating activities 105 183 Goodwill intangibles Software Total $m $m $m $m Investing activities Cost Change in amounts due from subsidiaries 47 70 Balance at 1 January 2015 51 51 Purchase of property, plant and equipment 3 Additions transfers from subsidiaries 145 10 155 Purchase of intangible assets 15 31 Remeasurement 8 8 Proceeds from disposal of intangible assets 9 Balance at 1 January 2016 43 145 10 198 Investments designated at fair value 20 Additions Transfers to subsidiaries 140 3 137 Investment in subsidiaries 2 24 Transfer to investment in subsidiaries 43 43 Acquisition of business undertakings net of cash acquired 516 Disposals 5 5 Interest income 3 4 Balance at 31 December 2016 13 13 Net cash used in investing activities 473 93 Amortisation Financing activities Balance at 1 January 2015 Decrease in collateralized cash 5 Charge for the year 1 1 Proceeds from issue of new shares 1 Balance at 1 January 2016 1 1 Proceeds from issue of long term financial debts 405 512 Repayment of longterm financial debts 260 66 Charge for the year 2 2 Repayment of short-term debts 247 Transfers to subsidiaries 3 3 Interest paid 33 27 Balance at 31 December 2016 Dividends paid 77 64 Carrying amount Cumulative effect of change in fair value 1 At 31 December 2016 13 13 Proceeds from co-development and earn out payment agreement, net 2 17 At 31 December 2015 43 144 10 197 Net cash generated from financing activities 37 130 In 2015 an adjustment of $8 million was made to the provisional goodwill recognised on the acquisition of Bedford as a result of the adjustment to Net decrease increase in cash and cash equivalents 331 220 property, plant and equipment, inventory and deferred taxes made prior to the end of the measurement period on 15 July 2015.
Cash and cash equivalents at beginning of year 363 143 Cash and cash equivalents at end of year 32 363 Annual Report 2016 203 194 Hikma Pharmaceuticals plc Annual Report 2016 195
